Study of BLU-808 in Allergic Rhinoconjunctivitis

Key Inclusion Criteria

• Adults, 18 years of age or older, willing to provide written informed consent, and willing to comply with all study requirements.
• History (>2 years) of ragweed-induced ARC.
• A positive ragweed skin prick test (mean diameter of ≥ 5 mm) in the last 6 months.
• Must meet clinically relevant nasal and ocular symptoms as defined by the protocol.

Key Exclusion Criteria

Participants are excluded from the study if any of the following criteria are met:

• Receiving medications (oral, nasal, topical, ocular, or injectable) to treat their ragweed or other allergy symptoms and/or receiving any medications that impact participants' safety or interfere with study assessments or interpretation of study results.
• Have active rhinitis, sinusitis, and/or other severe allergies not associated with the ragweed pollen that may interfere with study symptom assessments.
• Any prior or ongoing clinically significant illness, medical or psychiatric condition, surgical history, or physical finding that may interfere with the assessment or interpretation of study results.
• Clinically significant moderate to severe, uncontrolled cardiovascular, renal or hepatic disease.
• Significant bleeding risk or coagulation disorders.
• Any form of smoking, vaping or history of alcohol and drug abuse.
• Any malignancy within the past 5 years prior to Screening/AEC 1, except for basal cell or squamous cell carcinomas of the skin or carcinoma in situ.
• Inadequately controlled asthma that could affect the safety of the participant or interfere with the assessment or interpretation of study results.
• Known active/latent infection (viral, bacterial, fungal, helminth, or mycobacterial) such as tuberculosis, hepatitis B, hepatitis C, AIDS-related illness, or COVID-19 infection.
• History of sinonasal conditions that may confound the assessment or interpretation of study results.